Suppr超能文献

老年人膀胱癌

Bladder cancer in the elderly.

作者信息

Shariat Shahrokh F, Milowsky Matthew, Droller Michael J

机构信息

Division of Urology, Sidney Kimmel Center for Prostate and Urologic Cancer, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

出版信息

Urol Oncol. 2009 Nov-Dec;27(6):653-67. doi: 10.1016/j.urolonc.2009.07.020.

Abstract

INTRODUCTION

Age is now widely accepted as the greatest single risk factor for developing bladder cancer, and bladder cancer is considered as primarily a disease of the elderly. Because of the close link between age and incidence of bladder cancer, it can be expected that this disease will become an enormous challenge with the growth of an aging population in the years ahead.

METHODS

Using MEDLINE, a search of the literature between January 1966 and July 2007 was performed to describe normative physiologic changes associated with aging, elucidate genetic and epigenetic alterations that associate aging with bladder cancer and its phenotypes; and to characterize how aging influences efficacies, risks, side effects, and potential complications of the treatments needed for the various stages of bladder cancer.

RESULTS

We discuss influence of aging on host physiology, genetic and epigenetic changes, environmental influences, and host factors in the development and treatment of bladder cancer. Treatments with intravesical bacille Calmette Guerin, radical cystectomy, and perioperative chemotherapy are less well tolerated and have poorer response in elderly patients compared with their younger counterparts. Elderly patients face both clinical and broader institutional barriers to appropriate treatment and may receive less aggressive treatment and sub-therapeutic dosing. However, when appropriately selected, elderly patients tolerate and respond well to cancer treatments.

CONCLUSIONS

The decision to undergo treatment for cancer is a tradeoff between loss of function and/or independence and extension of life, which is complicated by a host of concomitant issues such as comorbid medical conditions, functional declines and "frailty", family dynamics, and social and psychologic issues. Chronological age should not preclude definitive surgical therapy. It is imperative that healthcare practitioners and researchers from disparate disciplines collectively focus efforts towards gaining a better understanding of what the consequences of bladder cancer and its treatments are for older adults and how to appropriately meet the multifaceted medical and psychosocial needs of this growing population.

摘要

引言

年龄现已被广泛认为是患膀胱癌的最大单一风险因素,膀胱癌主要被视为一种老年疾病。由于年龄与膀胱癌发病率之间存在密切联系,预计随着未来老年人口的增长,这种疾病将成为一个巨大的挑战。

方法

利用医学文献数据库(MEDLINE),检索了1966年1月至2007年7月期间的文献,以描述与衰老相关的正常生理变化,阐明将衰老与膀胱癌及其表型联系起来的遗传和表观遗传改变;并描述衰老如何影响膀胱癌各个阶段所需治疗的疗效、风险、副作用和潜在并发症。

结果

我们讨论了衰老对宿主生理学、遗传和表观遗传变化、环境影响以及膀胱癌发生和治疗中的宿主因素的影响。与年轻患者相比,老年患者对卡介苗膀胱灌注、根治性膀胱切除术和围手术期化疗的耐受性较差,反应也较差。老年患者在接受适当治疗方面面临临床和更广泛的制度障碍,可能接受的治疗不够积极,剂量也不足。然而,经过适当选择,老年患者对癌症治疗的耐受性和反应良好。

结论

决定接受癌症治疗是在功能丧失和/或独立性丧失与延长生命之间进行权衡,这因一系列伴随问题而变得复杂,如合并症、功能衰退和“虚弱”、家庭动态以及社会和心理问题。实际年龄不应排除确定性手术治疗。至关重要的是,来自不同学科的医疗从业者和研究人员应共同努力,更好地了解膀胱癌及其治疗对老年人的后果,以及如何适当地满足这一不断增长的人群多方面的医疗和心理社会需求。

相似文献

1
Bladder cancer in the elderly.
Urol Oncol. 2009 Nov-Dec;27(6):653-67. doi: 10.1016/j.urolonc.2009.07.020.
3
Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
J Urol. 2017 May;197(5):1189-1199. doi: 10.1016/j.juro.2016.12.090. Epub 2016 Dec 24.
4
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.
5
Bladder Cancer: A Review.
JAMA. 2020 Nov 17;324(19):1980-1991. doi: 10.1001/jama.2020.17598.
8
Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
BJU Int. 2013 May;111(6):984-7. doi: 10.1111/j.1464-410X.2012.11778.x. Epub 2013 Jan 25.
10
[Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies].
Urologe A. 2012 Jun;51(6):820-8. doi: 10.1007/s00120-011-2769-2.

引用本文的文献

2
3
Novel Urinary Biomarkers for the Detection of Bladder Cancer.
Cancers (Basel). 2025 Apr 10;17(8):1283. doi: 10.3390/cancers17081283.
4
Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2425529. doi: 10.1080/21645515.2024.2425529. Epub 2024 Nov 13.

本文引用的文献

1
Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits?
J Urol. 2010 Jun;183(6):2171-7. doi: 10.1016/j.juro.2010.02.015.
2
The prognostic significance of advanced age in patients with bladder cancer treated with radical cystectomy.
BJU Int. 2009 Feb;103(4):480-3. doi: 10.1111/j.1464-410X.2008.08033.x. Epub 2008 Oct 16.
3
The aging population--is there a role for endocrine interventions?
Growth Horm IGF Res. 2009 Apr;19(2):89-100. doi: 10.1016/j.ghir.2008.09.002. Epub 2008 Nov 1.
5
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology.
Eur Urol. 2009 Jan;55(1):164-74. doi: 10.1016/j.eururo.2008.07.031. Epub 2008 Jul 18.
7
Management of hypertension and cerebrovascular disease in the elderly.
Am J Med. 2008 Aug;121(8 Suppl):S23-31. doi: 10.1016/j.amjmed.2008.05.019.
8
Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention.
J Leukoc Biol. 2008 Oct;84(4):900-14. doi: 10.1189/jlb.0108023. Epub 2008 Jul 2.
9
Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.
Expert Rev Anticancer Ther. 2008 Jul;8(7):1103-10. doi: 10.1586/14737140.8.7.1103.
10
Telomere dysfunction and tumour suppression: the senescence connection.
Nat Rev Cancer. 2008 Jun;8(6):450-8. doi: 10.1038/nrc2393.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验